Bio-Techne Corporation logo

Bio-Techne Corporation (TECH)

Market Closed
3 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
53. 14
-0.04
-0.08%
$
8.13B Market Cap
49.99 P/E Ratio
0.32% Div Yield
843,100 Volume
1.99 Eps
$ 53.18
Previous Close
Day Range
52.7 53.62
Year Range
46.01 83.62
Want to track TECH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 37 days
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

Zacks | 5 days ago
Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide.

Prnewswire | 1 week ago
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

Prnewswire | 3 weeks ago
Why Is Techne (TECH) Down 3% Since Last Earnings Report?

Why Is Techne (TECH) Down 3% Since Last Earnings Report?

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

Zacks | 4 weeks ago
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.

Zacks | 1 month ago
Bio-Techne to Present at Investor Conferences

Bio-Techne to Present at Investor Conferences

MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at Click Here About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Prnewswire | 1 month ago
CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER

CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER

Antwerp, May 28, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) (“Golden Ocean”) are pleased to announce that they have signed an agreement and plan of merger (the “Merger Agreement”) for a stock-for-stock merger, as contemplated by the term sheet previously announced on 22 April 2025. The transaction is structured as a merger, with Golden Ocean merging with and into CMB.TECH Bermuda Ltd.

Globenewswire | 1 month ago
CMB.TECH announces Q1 2025 results

CMB.TECH announces Q1 2025 results

CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the first quarter ended 31 March 2025. HIGHLIGHTS Financial highlights: Profit of USD 40.4 million in Q1 2025 CMB.TECH increases its contract backlog by USD 921 million (to USD 2.94 billion) Corporate highlights: CMB.TECH buys Hemen stake in Golden Ocean Term sheet signed for a stock-for-stock merger transaction between CMB.TECH and Golden Ocean Fleet highlights: Fortescue and CMB.TECH sign agreement for ammonia-powered Newcastlemax CMB.TECH and MOL sign landmark agreement for nine ammonia-powered vessels Delivery of 5 newbuilding vessels: Mineral Portugal, Mineral Osterreich, Mineral Suomi, Mineral Sverige and CTV Hydrocat 60 Previously announced sales generated a capital gain of USD 46.25 million: Suezmax Cap Lara (2007, 158,826 dwt), VLCC Alsace (2012 – 299,999 DWT) and Windcat 6 Sale of three VLCCs in Q1 2025, Iris (2012, 314,000 dwt), Hakata (2010, 302,550 dwt) & Hakone (2010, 302,624 dwt) as part of the fleet rejuvenation strategy.

Globenewswire | 1 month ago
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

MINNEAPOLIS , May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13 th – 17th at the New Orleans Ernest N. Morial Convention Center.

Prnewswire | 1 month ago
CMB.TECH announces Q1 2025 results on 21/05/25

CMB.TECH announces Q1 2025 results on 21/05/25

Antwerp, May 12, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2025 earnings prior to market opening on Thursday 21 May 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.

Globenewswire | 1 month ago
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at Click Here

Prnewswire | 1 month ago
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Zacks | 1 month ago
Loading...
Load More